Dana dhuwit saben siji saham neurometrix.com (NURO)

NeuroMetrix, Inc. (NURO) develops Quell devices to combat neuropathy, which this cash per share chart on GURU.Markets links to the market trend. Distribution relies on third-party electronics and logistics contractors, although limited sales scale inflates unit costs. Meanwhile, 6.33 represents the latest metric reading, determining the business's current liquid reserve.
Rincian metrik komprehensif lan analitis NeuroMetrix Corporation (NURO)

Interest in NeuroMetrix, Inc. (NURO) shares requires a liquidity check via the amount of free cash per share. This metric reflects the actual remaining capital net of liabilities, distributed across the total equity. Analyzing cash per share allows for an assessment of the company's ability to fund the development of Quell devices without external borrowing. Growth in this indicator confirms the business's resilience in the non-pharmacological pain management market. This is a key indicator of the issuer's solvency and capital quality.